# QoL-Comparison Between Trabectedin/PLD and Pt-based Therapy in Patients With Pt-sensitive Recurrent Ovarian Cancer

> **NCT03164980** · PHASE4 · TERMINATED · sponsor: **North Eastern German Society of Gynaecological Oncology** · enrollment: 89 (actual)

## Conditions studied

- Quality of Life
- Ovarian Cancer
- Recurrent Ovarian Carcinoma

## Interventions

- **DRUG:** Trabectidin (Yondelis)

## Key facts

- **NCT ID:** NCT03164980
- **Lead sponsor:** North Eastern German Society of Gynaecological Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-02-01
- **Primary completion:** 2023-08-08
- **Final completion:** 2023-08-08
- **Target enrollment:** 89 (ACTUAL)
- **Why stopped:** A total of 204 patients were planned to be randomized. Due to slow recruitment of the trial, the recruitment was prematurely terminated after randomization of the 89th patient.
- **Last updated:** 2025-03-20

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03164980

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03164980, "QoL-Comparison Between Trabectedin/PLD and Pt-based Therapy in Patients With Pt-sensitive Recurrent Ovarian Cancer". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03164980. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*